

Contents

Part I Biology

- 1 Update on the Biology of Myeloproliferative Neoplasms** 3
Robert Kralovics
- 2 Do We Need Biological Studies for Patient Management? . . .** 11
Moosa Qureshi and Claire Harrison

Part II General Issues in the Management of MPNs

- 3 Critical Issues About the Diagnosis of MPNs:
Bone Marrow Histopathology** 19
Jürgen Thiele and Hans Michael Kvasnicka
- 4 Critical Issues About the Diagnosis of Myeloproliferative
Neoplasms: World Health Organization Classification** 37
Mary Frances McMullin
- 5 Patient's Information and Examinations Needed Before
Planning Therapy in the Myeloproliferative Neoplasms** 47
Francisco Cervantes and Juan-Carlos Hernández-Boluda
- 6 Mechanisms of Thrombogenesis** 57
Anna Falanga, Laura Russo, and Marina Marchetti

Part III Specific Issues of Treatment in PV and ET

- 7 Risk Classification** 71
Guido Finazzi
- 8 Goal of Therapy and Monitoring the Response
in Polycythemia Vera and Essential Thrombocythemia** 85
Jean-Jacques Kiladjian
- 9 First-Line Therapy and Special Issues Management
in Polycythemia Vera and Essential Thrombocythemia** 93
Tiziano Barbui
- 10 Primary and Secondary Antithrombotic Prophylaxis** 105
Leonardo Di Gennaro and Raffaele Landolfi

11 Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options	119
Alessandro M. Vannucchi	
12 Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms	131
Madappa N. Kundra, Raoul Tibes, and Ruben A. Mesa	

Part IV Treatment of PMF

13 Current Clinical Needs	149
Giovanni Barosi	
14 Risk Stratification in PMF	163
Francesco Passamonti	
15 Nontransplant Treatment Options for Myelofibrosis: How to Treat Anemia, Splenomegaly, Constitutional Symptoms, and Extramedullary Disease	177
Ayalew Tefferi	
16 Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis	187
Nicolaus Kröger	

Part V Research Issues and Perspectives

17 A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy	203
Animesh Pardanani	
18 Ongoing Clinical Trials in Myeloproliferative Neoplasms	215
Fabio P.S. Santos and Srđan Verstovsek	
Index	233